Operating Model, Governance & Ways of Working End-to-end market access strategy frame: What is the winning ambition? Where to play? How to win? How to execute? (decision gates, RASIC, KPIs). Cross-functional cadence (MAx-style): roles, coordination across brand, HEOR, medical, sales, finance; rapid-response cycles for policy/competitive shifts.

End-to-end market access strategy frame

Use a simple, repeatable frame to keep strategy choices explicit and testable throughout development and launch:

• What is the winning ambition? Define clear access objectives aligned to the brand’s commercial goals (e.g., target time-to-coverage, acceptable net price corridor, population breadth). Ensure cross-functional alignment on specific access goals from the outset.
• Where to play? Ground choices in a structured landscape assessment: treatment context, priority stakeholders (plans, PBMs, IDNs, value assessors), likely utilization controls, and trade-offs across access routes.
• How to win? Decide how you will define and communicate value, and which pricing, contracting, affordability, and fulfillment approaches fit each segment.
• How to execute? Translate strategy into prioritized cross-functional actions, continuously monitor results, and adjust to market signals. 

Governance: decision gates, role clarity (RASIC), and KPIs

• Decision gates. Institutionalize 5–7 decision checkpoints (e.g., End of Phase 2 design lock; Phase 3 protocol/endpoint lock; HTA/scientific advice go/no-go; pre-submission readiness; pricing/contracting sign-off; launch readiness; 100-day post-launch review) that force evidence, value narrative, and channel plans to converge. Each gate should confirm “what changes” on the four strategic questions above and trigger plan adjustments where needed. (Continuous monitoring and plan adjustment are core execution principles.)
• Role clarity (RASIC). Document who is Responsible, Accountable, Supporting, Informed, Consulted for each deliverable (e.g., payer evidence plan, core value dossier, price corridor, contracting playbook, channel/fulfillment). Clear roles and responsibilities—and coordination across affiliates—are highlighted as prerequisites to effective execution.
• KPIs. Track a short list that reflects ambition and execution quality: time to first major-payer coverage; share of covered lives without step/PA; net price vs. corridor; HTA outcomes vs. base case; guideline inclusion timelines; patient out-of-pocket (OOP) at point of sale; speed of resolving access barriers. (KPIs exist to enable the “monitor and adjust” loop.) 

Cross-functional cadence (MAx-style)

• Cadence and forums. Run a monthly access steering (brand + market access + HEOR + medical + finance + sales/field access + trade/channel) plus quarterly affiliate syncs; use working sprints to close evidence or policy gaps between gates. Cross-functional coordination and adequate resourcing across these teams are repeatedly underscored.
• Ways of working. Start early, keep work interdependent, and emphasize coordination as an active leadership function—not passive cooperation. These management principles matter in health organizations where outcomes depend on many independent decisions.
• Rapid-response cycles. Build flexibility to adapt to changes in customers, competition, and policy/economic context; make explicit trade-offs as conditions shift. 

Practical deliverables and ownership (illustrative)

• Evidence & value: payer evidence plan, base CEA/BIA, RWE plan, core value dossier (Lead: HEOR/Market Access; Support: Medical, Biostats).
• Pricing & contracting: price corridor, discount/REB policy, archetype-specific playbooks (Lead: Market Access/Pricing; Support: Finance, Legal).
• Policy & guidelines: engagement with value assessors/guideline bodies; medical education (Lead: Medical/Policy; Support: Access).
• Channel & fulfillment: site-of-care, distribution, specialty channel, OOP mapping (Lead: Trade/Channel; Support: Access, Finance). 

Case Study Section (templates + concise exemplars)

How to write each case (copy/paste template)

• Context (Archetype / Market) — Therapy area, product profile, target population; key markets and payers. (Anchor to archetype lens to avoid one-size-fits-all.)
• Access challenge — What specific barrier threatened launch (e.g., expected UM, competing SoC, affordability, uncertain outcomes)?
• Evidence/analytics approach — Comparator logic, endpoints/PROs, HEOR (CEA/BIA), RWE plan.
• Cross-functional plan — Who led what (MA/HEOR/Medical/Brand/Finance/Trade), sequence of activities (advice, dossiers, education).
• Pricing/contracting choice — Rationale vs. payer segments; affordability/OOP mitigation; channel implications.
• Launch outcome — Coverage timing, restrictions, net price vs. plan, guideline status. (Tie back to KPIs.)
• Post-launch learning — What to scale or change (e.g., additional evidence, contract tweaks, indication sequencing). 

Concise exemplars (for your paper)

A) Oncology (Archetype: Oncology; US + EU5)

• Context. IV onco-biologic addressing high unmet need; biomarker-defined subpopulation.
• Access challenge. Anticipated UM due to endpoint mix (PFS vs. OS) and site-of-care costs.
• Evidence/analytics. Early OS-relevant endpoint plan; validated QoL instruments; targeted RWE to fill gaps.
• Cross-functional plan. Engage KOLs/medical societies, value assessors (e.g., NCCN/ICER) for aligned narratives; coordinate with trade for channel/COEs.
• Pricing/contracting. Segment payers by benefit design/control; combine base rebates with center-of-excellence support and pathway alignment.
• Outcome & learning. Faster guideline inclusion; coverage with manageable restrictions; iterate value story as RWE matures. 

B) High-volume specialty (Archetype: Immunology; US)

• Context. SC specialty drug competing in a crowded class.
• Access challenge. PBM consolidation and rebate dynamics; risk of step-therapy and tier-3 coinsurance.
• Evidence/analytics. Indirect comparisons to clarify differentiation; BIA to frame affordability.
• Cross-functional plan. Identify priority payer segments by ability to control utilization; align price/contract levers by segment and geography.
• Pricing/contracting. Traditional rebates in tight PBM segments; outcomes-linked terms (limited scope) with IDNs to support pathway adoption.
• Outcome & learning. Achieved target lives on preferred tiers; preserved net price corridor via targeted, not universal, concessions. 

C) Rare / Cell & Gene (Archetype: Rare incl. CGT; US + EU)

• Context. One-time therapy with long-horizon outcomes; few centers of excellence.
• Access challenge. High uncertainty on durability and budget impact; need for granular stakeholder education.
• Evidence/analytics. Prospectively designed registry + long-term outcomes; burden-of-illness and care pathway studies for payers and providers.
• Cross-functional plan. Coordinate medical, policy/government affairs, and access with COEs and public-health entities; secure distribution/fulfillment readiness.
• Pricing/contracting. Consider outcomes-linked arrangements where infrastructure allows; sequence indications to balance evidence maturation and affordability.
• Outcome & learning. Managed initial uncertainty while building evidence; refined contracts post-readout and expanded access centers. 

(These exemplars are pattern-based and map to the five archetypes described in the research; they’re intended as fill-in-the-blanks shells you can adapt to your asset and geographies.)